Data on the in vitro and in vivo anti-tumor effects of itraconazole, paclitaxel, and the two in combination in HT-29 and YM-1 cancer cell line and HT-29 colon cancer xenograft models

伊曲康唑、紫杉醇及其联合用药在HT-29和YM-1癌细胞系以及HT-29结肠癌异种移植模型中的体外和体内抗肿瘤作用数据

阅读:1

Abstract

Colon cancer is one of the fatal cancers in the world that metastatic potential and resistance to chemotherapy drugs are outstanding causes of cancer-induced mortality [1], [2], [3], [4]. We have investigated in vitro and in vivo anti-cancer effect of itraconazole and paclitaxel alone and their anti-cancer synergistic effect through MTT assay in YM-1 and HT-29 cell lines and in HT-29 tumor-bearing nude mice. Histopathological experiment was done for further assessment. Also, we evaluated the inhibitory effect of itraconazole on P-gp using specific in vivo biodistribution through (99m)Tc-MIBI uptake. (99m)Tc-MIBI, a myocardial perfusion imaging agent, is a useful radiotracer in diagnosis of some tumors and the liver and tumor accumulation of (99m)Tc-MIBI is changed by P-gp regulators [5], [6], [7], [8]. The data presented in this article are related to the research paper entitled "Itraconazole synergistically increases therapeutic effect of paclitaxel and 99mTc-MIBI accumulation, as a probe of P-gp activity, in HT-29 tumor-bearing nude mice". We hope our preliminary data to be helpful to design the chemotherapy regimen schedule with Itraconazole and Paclitaxel.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。